Detalhe da pesquisa
1.
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Blood
; 139(5): 717-731, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34657149
2.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Mol Cancer
; 22(1): 138, 2023 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596643
3.
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Br J Haematol
; 202(5): 985-994, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37357529
4.
Precision cancer medicine: Concepts, current practice, and future developments.
J Intern Med
; 294(4): 455-481, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641393
5.
Rapid and highly sensitive approach for multiplexed somatic fusion detection.
Mod Pathol
; 35(8): 1022-1033, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347250
6.
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Blood
; 136(14): 1657-1669, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32573700
7.
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.
Pediatr Blood Cancer
; 69(1): e29316, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34546642
8.
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1764-1776, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780709
9.
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
BMC Cancer
; 21(1): 833, 2021 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34281526
10.
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 21(1): 121-133, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31812554
11.
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Lancet Oncol
; 21(1): 134-144, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31780255
12.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Lancet Oncol
; 21(4): 531-540, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105622
13.
Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Pediatr Blood Cancer
; 67(1): e28032, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31595663
14.
Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine.
Mol Ther
; 27(1): 200-218, 2019 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509566
15.
Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.
Pediatr Blood Cancer
; 66(2): e27487, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30378286
16.
Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Clin Trials
; 16(6): 635-644, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538815
17.
A new generation of comprehensive precision oncology trials.
Lancet Oncol
; 24(12): e452, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039994
18.
Outcome of children and adolescents with central nervous system tumors in phase I trials.
J Neurooncol
; 137(1): 83-92, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29236237
19.
Precision medicine in pediatric oncology.
Curr Opin Pediatr
; 30(1): 17-24, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29189430
20.
From class waivers to precision medicine in paediatric oncology.
Lancet Oncol
; 18(7): e394-e404, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677575